MSK-ACCESS
Diagnostic TestMSK-ACCESS is a ctDNA sequencing assay
NCT Number: NCT07399977
The purpose of this study is to find out whether a software tool, ctDNA/VTE (Venous Thromboembolism) risk score model, is an effective way to predict the likelihood of VTE coming back in people who have received anticoagulant treatment.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Royal North Shore Hospital, Australia, Sydney, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Diagnosis of DVT requires evidence of one or more filling defects at compression ultrasonography, venography, CT venography, or MR venography involving at least the popliteal or more proximal veins.
Diagnosis of PE requires an intraluminal filling defect in segmental or more proximal arteries.
Exclusion criteria
MSK-ACCESS is a ctDNA sequencing assay
Machine learning Venous Thromboembolism/VTE risk score mode
Time frame: 6 months
Evaluate the cumulative incidence of recurrent Venous Thromboembolism/VTE at 6 months following discontinuation of anticoagulation in participants with low risk DNA liquid biopsy-based model.
Contact information is provided by the study sponsor or research team.
Jeffrey Zwicker, MD
CONTACT
Justin Jee, MD, PhD
CONTACT
Memorial Sloan Kettering Cancer Center
Other
A Nonrandomized Trial Using DNA Liquid Biopsies to Guide Anticoagulation For Patients With Cancer-Associated Thromboembolism
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05701917
Cardiovascular Diseases, Deep Venous Thrombosis
Scottsdale, Arizona, United States
View Trial DetailsNCT04211181
Cardiovascular Diseases, Deep Venous Thrombosis
Beijing, Beijing Municipality, China
View Trial DetailsNCT06495996
Cardiovascular Diseases, Deep Venous Thrombosis
Newport Beach, California, United States
View Trial DetailsNCT03212365
Cardiovascular Diseases, Deep Venous Thrombosis
Stanford, California, United States
View Trial Details